RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nunzia Pharmaceutical Stock

Nunzia Pharmaceutical ROCE 2024

Nunzia Pharmaceutical ROCE

828.85

Ticker

NUNZ

ISIN

US67097W1027

In 2024, Nunzia Pharmaceutical's return on capital employed (ROCE) was 828.85, a 0% increase from the 0 ROCE in the previous year.

Nunzia Pharmaceutical Aktienanalyse

What does Nunzia Pharmaceutical do?

Nunzia Pharmaceuticals Corp is an international pharmaceutical company specializing in the development and marketing of innovative and effective drugs and medical devices. The company was founded in 2010 and is headquartered in California, USA. The business model of Nunzia Pharmaceuticals is focused on researching diseases that have been difficult or impossible to therapeutically treat in the past. The company is constantly working to develop new drugs and devices that prove to be effective treatment options. Nunzia Pharmaceuticals places great importance on comprehensive clinical trials to ensure the safety and efficacy of its products. In addition to researching and developing new medical solutions, Nunzia Pharmaceuticals has also developed a variety of medical devices that are available on the market. These devices offer innovative and effective treatment options for a variety of diseases that can improve patients' quality of life. Nunzia Pharmaceuticals is divided into different divisions in order to focus research and development on different areas. These divisions are oncology, neurology, cardiology, and orthopedics. In oncology, the company is working to develop new drugs that provide effective treatment options for various types of cancer. In neurology, the company is focused on researching treatment options for neurodegenerative diseases such as Alzheimer's and Parkinson's. In cardiology, Nunzia Pharmaceuticals is involved in the development of drugs and devices that prevent the onset of cardiovascular diseases. In orthopedics, the company has developed a variety of medical devices that improve the quality of life for patients with bone or joint diseases. An example of an innovative drug from Nunzia Pharmaceuticals is Alpharolix, which is used to treat certain types of cancer. This drug has proven to be very effective and is used worldwide to help many patients with this difficult condition. Another innovative product from Nunzia Pharmaceuticals is the carpal metacarpal joint prosthesis system, which provides improved quality of life for patients with advanced joint diseases. Over the years, Nunzia Pharmaceuticals has achieved many successes and has become a leading company in the field of medical research and development. The company has filed numerous patents and introduced a variety of medical innovations to the market. Today, the name Nunzia is globally recognized for quality, effectiveness, and innovation in medical research and development. Overall, Nunzia Pharmaceuticals is a very important player in the market of medical research and development. The company has established itself as a reliable partner for doctors, medical facilities, and patients in recent years and has set a goal to develop further groundbreaking innovations to effectively treat diseases worldwide. Nunzia Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Nunzia Pharmaceutical's Return on Capital Employed (ROCE)

Nunzia Pharmaceutical's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Nunzia Pharmaceutical's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Nunzia Pharmaceutical's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Nunzia Pharmaceutical’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Nunzia Pharmaceutical stock

What is the ROCE (Return on Capital Employed) of Nunzia Pharmaceutical this year?

The ROCE of Nunzia Pharmaceutical is 828.85 undefined this year.

How has the ROCE (Return on Capital Employed) of Nunzia Pharmaceutical developed compared to the previous year?

The ROCE of Nunzia Pharmaceutical has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Nunzia Pharmaceutical?

A high Return on Capital Employed (ROCE) indicates that Nunzia Pharmaceutical has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Nunzia Pharmaceutical?

A low ROCE (Return on Capital Employed) can indicate that Nunzia Pharmaceutical has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Nunzia Pharmaceutical impact the company?

An increase in the ROCE of Nunzia Pharmaceutical can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Nunzia Pharmaceutical affect the company?

A decrease in ROCE of Nunzia Pharmaceutical can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Nunzia Pharmaceutical?

Some factors that can affect Nunzia Pharmaceutical's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Nunzia Pharmaceutical so important for investors?

The ROCE of Nunzia Pharmaceutical is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Nunzia Pharmaceutical take to improve the ROCE?

To improve the ROCE, Nunzia Pharmaceutical can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Nunzia Pharmaceutical pay?

Over the past 12 months, Nunzia Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nunzia Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Nunzia Pharmaceutical?

The current dividend yield of Nunzia Pharmaceutical is .

When does Nunzia Pharmaceutical pay dividends?

Nunzia Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nunzia Pharmaceutical?

Nunzia Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Nunzia Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nunzia Pharmaceutical located?

Nunzia Pharmaceutical is assigned to the '-' sector.

Wann musste ich die Aktien von Nunzia Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nunzia Pharmaceutical from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Nunzia Pharmaceutical pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Nunzia Pharmaceutical in the year 2023?

In the year 2023, Nunzia Pharmaceutical distributed 0 USD as dividends.

In which currency does Nunzia Pharmaceutical pay out the dividend?

The dividends of Nunzia Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nunzia Pharmaceutical

Our stock analysis for Nunzia Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nunzia Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.